Linked Life Data

11831831

Source:http://linkedlifedata.com/resource/pubmed/id/11831831

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-2-7
pubmed:abstractText
Current systemic treatment of metastatic renal cell carcinoma revolves around the use of interleukin-2 and interferon-alpha, often in combination with 5-fluorouracil. This article looks at the currently reported response rates for these modalities. It also looks at current practice as regards maintenance treatment, i.e. the continued therapeutic regimen following the initial response to the induction immunotherapy cycles.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1368-5031
pubmed:author
pubmed:issnType
Print
pubmed:volume
56
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
36-9
pubmed:dateRevised
2007-2-14
pubmed:meshHeading
pubmed:articleTitle
Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
pubmed:affiliation
Department of Urology, Craigavon Area Hospital, Co Armagh, UK.
pubmed:publicationType
Journal Article, Review